Controlled Medicines in Indian Clinics: Schedule X, NDPS and Prescribing Boundaries
Separate drug classification, clinical assessment and permissions to possess or supply controlled medicines; build a product-specific review and stock handover.
Ask whether payment, referral revenue or a commercial partnership can change what a clinician sees first in drug search, laboratory suggestions or referral directories. Require clear ranking explanations and test comparable results with commercial influence removed. A “sponsored” label alone does not establish clinical suitability, patient choice or professional acceptability.
Indian clinic owners, doctors and procurement teams reviewing EMRs, medicine catalogues, referral marketplaces and diagnostic-booking integrations.
A clinic may buy software for appointments and records yet encounter product suggestions inside prescribing, test ordering or referral screens. These suggestions can affect decisions even when nobody describes them as advertising. The first result, a preselected item or a highlighted “recommended” option can receive disproportionate attention during a busy consultation.
Map where money could influence visibility: paid placement, partner-only catalogues, commissions, exclusive integrations, discounts or commercial defaults. Do not assume a familiar brand name or a clinically styled badge explains why the item appears first.
Keep the review specific. A supplier’s stock availability can be useful operational information; it is different from a claim that its product is clinically preferred. A directory sorted by distance is different from one whose top position is sold. The interface should help the user understand those distinctions.
The procurement objective in this guide is independence and transparency in clinical workflows. It is a proposed evaluation standard, not a claim that Indian law contains one universal rule prescribing the exact ranking algorithm every EMR must use.
NMC’s ethics code addresses referral commissions and related professional conduct. The Department of Pharmaceuticals’ UCPMP framework addresses pharmaceutical marketing within its scope. Neither should be paraphrased here as a complete technical standard for search ranking in every software product.
Review the doctor’s obligations, the clinic’s commercial arrangement and the vendor’s behaviour separately. A clause in a software contract does not establish that a particular incentive is professionally acceptable. Obtain appropriate advice where a relationship involves referrals, benefits or potentially conflicted recommendations.
Ask who receives the economic benefit and for what activity. A transparent software subscription differs from payment tied to a particular clinical selection. The full arrangement matters, including indirect rewards, staff targets and patient-facing discounts.
If an arrangement is unclear, document the question and resolve it before enabling the affected recommendation or referral feature. A vendor’s assurance that “everyone does this” is not evidence about the clinic’s obligations or the patient’s interests.
Source: NMC: Code of Medical Ethics Regulations, 2002
Source: Department of Pharmaceuticals: UCPMP 2024 and subsequent amendments
A ranking explanation should describe the factors that matter to the user: exact ingredient or test match, formulation, location, availability, quality evidence where relevant and commercial placement. It does not need to expose proprietary source code to answer whether payment can change prominence.
Distinguish relevance from endorsement. A medicine catalogue match is not a patient-specific recommendation, and a laboratory being bookable through an integration is not proof that it is the best destination. Avoid labels that imply independent clinical evaluation when the system is only filtering a commercial directory.
The table provides questions for an original procurement review. It is not an approved ranking model or a legal classification of every advertising arrangement.
On a narrow screen, scroll the table horizontally to read all columns.
| Signal | Potentially useful meaning | Question to ask |
|---|---|---|
| Exact search match | The item matches the requested ingredient, form or service | Can payment displace a closer match? |
| Availability | A supplier or appointment is currently accessible | Is stock status being presented as clinical superiority? |
| Distance or convenience | A nearby service may be easier to reach | Are non-partner options hidden from the comparison? |
| Quality indicator | A defined evidence source supports a specific claim | Who verified it, when and for what scope? |
| Sponsored or partner placement | A commercial relationship affects visibility | What changes when sponsorship is removed, and can the clinician avoid it? |
Use fictional searches and record the conditions: query, location, account, filters, catalogue version and time. Compare the same task with and without the commercial influence where the vendor can demonstrate that distinction. Change one factor at a time so a different result has an interpretable cause.
For a medicine search, inspect exact generic and formulation matches, brand ordering and any preselection. For a diagnostic directory, inspect service coverage, location and non-partner visibility. For referrals, examine whether the result order is affected by a fee or partnership rather than the displayed criteria.
Ask the vendor to explain a changed order and retain the explanation with the test. If the system cannot produce a comparison, request a clear statement of ranking factors and commercial controls, then record the visibility limitation. Do not describe untested independence as verified.
Repeat the comparison on the actual surfaces staff use, including mobile, autocomplete, favourites and generated patient instructions. A neutral full-results page is insufficient if a sponsored option is automatically selected before the user reaches it.
A clinician should be able to assess the appropriate option without being steered by an undisclosed commercial default. Where a clinical recommendation is made, preserve its patient-specific basis. Do not let the software’s preferred partner become the recorded rationale.
Patient choice needs a usable route. If a patient wants another pharmacy, laboratory or referral destination, determine whether the document and workflow support that choice. A technically exportable order is less useful if staff tell patients that only the integrated partner can accept it.
Keep price and availability information accurate about scope and timing. A displayed low price may exclude collection, reporting or another charge; an available slot may not offer the required service. The clinic should not turn an unverified commercial feed into a promise about care.
Review staff incentives and scripts alongside the interface. Even a transparent search screen can be undermined by targets that reward one destination. The clinic needs an honest account of who benefits and how choices are explained, not just a disclosure sentence in a policy page.
Describe the behaviour the clinic expects in the agreement or evaluation record. Avoid a broad phrase such as “commercial firewall” without defining its reach. Specify which clinical surfaces, partners, incentives and data uses are covered and how changes will be disclosed.
Ask what happens when the vendor introduces a new partnership or changes ranking factors. The clinic should have a practical review route and, where agreed, a way to disable affected features. A silent commercial change after onboarding can invalidate the original evaluation.
The outline below is an original discussion document, not a legal contract. Have the actual terms reviewed for the clinic’s circumstances.
Keep a small set of representative fictional searches and the expected review questions. Run them after a relevant integration or ranking change. The goal is to detect unexplained commercial influence, not to freeze every result order despite legitimate changes in availability or relevance.
Review patient complaints and staff workarounds for clues. Repeated reports that a preferred destination is difficult to choose, or that a particular brand appears regardless of the query, deserve investigation. Verify the behaviour before drawing conclusions about motive.
If a conflict is found, preserve the evidence, assess its reach and arrange an appropriate correction with the vendor and clinic leadership. Consider whether patient-facing instructions or staff scripts also need review. Do not solve a ranking problem only by hiding the word “sponsored”.
Record what was actually tested and what remains unknown. A procurement review can establish that a particular version behaved in a particular way; it cannot certify every future update or guarantee that a clinical choice is correct. Keep human accountability for care decisions explicit.
A fictional Surat clinic evaluates a diagnostic-booking screen. Its top result carries a “recommended” badge, but the vendor explains that the label means the test is available through an integrated partner, not that clinical quality has been independently compared. The clinic requests clearer availability wording, a visible route to other destinations and documentation of ranking factors. It then tests the generated patient instruction to ensure it does not convert the partner’s availability into a doctor’s endorsement. This is an interface and procurement review, not an allegation about any named vendor.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
A label improves visibility of a relationship but does not settle clinical suitability, professional obligations or the effect of the placement. Review the actual incentive, prominence, defaults and patient-choice route, with appropriate advice where required.
No. Availability is an operational fact, subject to verification. Clinical appropriateness depends on the patient and clinician’s assessment. The interface should not turn a supplier’s available stock into an unexplained recommendation.
No. It proposes a procurement standard for transparent, independent clinical workflows. Applicable professional and marketing obligations require separate review. The exact arrangement and the roles of the doctor, clinic and vendor matter.
Use the same fictional query and conditions, compare results with the commercial influence removed where demonstrable, and inspect defaults and patient outputs. Ask for a factor-level explanation and record anything the vendor cannot demonstrate.
No. It sets evaluation questions for any vendor, including Bractis. Verify the actual configuration, ranking explanation, commercial terms and change process in a demonstration and procurement review rather than treating an article as product evidence.
Updated on . Original procurement guidance, not a legal opinion, vendor certification or allegation about competitors. Professional and commercial arrangements need review in their actual context. No independent clinical or legal review is claimed.
Professional-conduct reference, including registration details, advertising and referral commissions. Apply the relevant provision to the practitioner and activity; this guide’s operational examples are original suggestions.
Official pharmaceutical-marketing code page includes the September 2025 amendment. Its scope is not a universal technical specification for ranking in clinic software.
Separate drug classification, clinical assessment and permissions to possess or supply controlled medicines; build a product-specific review and stock handover.
Create a practical prescription-sharing process for shared phones, caregiver requests, corrected PDFs and wrong-recipient incidents in Indian clinics.
Review doctor profiles, service pages, testimonials, metadata and agency campaigns against professional-ethics boundaries while improving useful patient information.
Bring fictional medicine, laboratory and referral searches to a Bractis demo. Ask for the ranking factors, commercial relationships and non-partner route, and document what is demonstrated and what remains unverified.
Request a clinic demo